THERAGEN

Theragen Bio Leading genome-based precision medicine

Theragen Bio a wide range of services such as customized diagnostic solution and next generation sequencing (NGS), clinical and medical big data business based on state-of-the-art genome sequencing and analysis technologies. We export genome analysis technologies to 40 countries as a leader in this “Precision Medicine” era. Read More

Theragen Etex Production and supply of about 200 medicines

Theragen Etex concentrates on First Generic, which was established in 1990, and manufacturing and distributing incrementally modified drugs (IMD). We have KGMP production facility, produce about 200 kinds of medicines, and supply them efficiently through 9 branches across the nation. Recently, we have been gearing up production of novel drugs. Read More

Theragen Etex group is a comprehensive pharmaceutical and biotechnology group providing outstanding genetic analysis services and progressing personalized new drug development.

Leadpharm
Pharmacy chain and distribution of medical supplies As a distribution chain, which was established through a joint venture by large domestic pharmacies, it supplies medicines, quasi-drugs, and health functional foods to domestic hospitals and pharmacies. It has secured competitiveness through differentiated products and is making every effort to create value for member companies. It is seeking greater customer convenience by opening a new Korean style drugstore called “Pharm Store” recently. Leadpharm Site
Theragen healthcare
Manufacturing and distribution of medical supplies It leads the manufacturing and distribution of medical supplies along with Daeil Pharm and Pharm Biotech, its affiliated companies. It self-develops, license-produces via OEM, and supplies pharmacies nationwide with multiple products including diabetes-related products (e.g. Nocodingone glucose detector) and functional bands. It also actively conducts research on cutting-edge medical equipment and quasi drugs to enhance corporate values. Theragen healthcare Site
Medpacto
Development of novel anticancer drug It is developing Vactosertib (TEW-7197), a novel anticancer drug which can strongly suppress Transforming Growth Factor (TGF-β) in a selective way. Safety verification and research on exploratory efficacy of this medicine through clinical trials in Korea and the US are smoothly underway. Since it is expected to be administered concomitantly with cancer immunotherapy, medical circles are paying attention. Medpacto Site
Theragen Genomecare
Non-invasive prenatal diagnosis service It provides various genetic information for pregnant women using the latest Bio-Informatics technology. Based on excellent researchers and internal and external medical networks, it is enhancing market competitiveness in the field of prenatal diagnosis such as non-invasive prenatal testing (NIPT) using next generation sequencing (NGS) and preimplantation genetic screening (PGS). Theragen Genomecare Site